Heymach J, et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.06.
Congressen IGCA en ESDE: beide geslaagd, en ook verbinding
jul 2025 | Maag-darm-leveroncologie
nov 2024 | Longoncologie
nov 2024 | Longoncologie
feb 2024 | Longoncologie
dec 2023 | Uro-oncologie
jun 2021 | Chirurgie, Maag-darm-leveroncologie
feb 2021 | Maag-darm-leveroncologie
sep 2024